Consent Documentation and Re-Consent After a Mid-Study Amendment
At a monitoring visit for a Phase II rheumatoid arthritis trial, the CRA reviews consent documents for eight enrolled participants. Three consent forms lack the signature of the person obtaining consent. One form was signed by a Spanish-speaking participant using an 'X'; the site's bilingual medical assistant served as interpreter, but the form lists the participant's adult son as witness, and the interpreter line is blank. The participant later says he did not understand that the study includes monthly blood draws and that he could withdraw at any time. Another participant enrolled on 4 March under consent version 2.1, but the current IRB-approved version 3.0, which adds a new warning about reactivation of hepatitis B, was approved on 1 March. The site has a screening queue and the principal investigator is traveling. The CRA asks the coordinator to 'clean this up before the close-out visit.'
1. Which consent problems require immediate escalation, and to whom? Explain how you would triage them.
Read the worked answer
Triage by threat to participant rights and safety, not by paperwork convenience.
The Spanish-speaking participant is highest priority. An 'X' signature can be acceptable only with a witness and an interpreter using an IRB-approved process; a family member as witness is not impartial, the interpreter line is blank, and the participant says he did not understand the blood draws or the right to withdraw. That calls the adequacy of consent into question. Stop relying on that consent, notify the PI immediately, contact the IRB and sponsor, and arrange re-consent with a qualified medical interpreter and an impartial witness. Do not let the son interpret; document the interpreter's identity and the participant's questions.
The version 3.0 issue is also urgent if 3.0 was the IRB-approved version on 4 March. Re-consent the participant with 3.0 and document the new hepatitis B warning. If the IRB had granted a transition period for 2.1, document that approval; do not assume.
Missing obtainer signatures are documentation deviations. Do not backdate. Create a memo identifying who obtained consent, when, and why the signature is missing; report the deviation per site SOP. The PI traveling does not excuse delay; contact by phone or email and document the instruction.
2. Draft the corrective and preventive action plan for the site, including re-consent decisions, documentation, and oversight.
Read the worked answer
The CAPA must address both the individual subjects and the system failure.
- Re-consent every affected participant using the current IRB-approved form and a qualified interpreter when needed. For the participant who did not understand key elements, re-consent is not a paperwork exercise: use a teach-back method, document the participant's questions, and confirm voluntariness. If he declines, document withdrawal or continued participation only after valid consent is obtained.
- Correct the consent documentation prospectively. Do not alter the original forms. Write a dated memo for each missing obtainer signature identifying the person who obtained consent from the source records and staff interviews, and attach it to the regulatory binder. Report the deviations to the IRB and sponsor per policy.
- Retrain all consent-designees on the site SOP: use only the current IRB-approved version, verify version dates against the enrollment date, use qualified interpreters and impartial witnesses, complete every signature and date field, and never allow family members to serve as interpreter and witness for the same participant.
- Audit all active consents within 5 business days, including screening consents, and have the PI review and sign the audit. Add a second-person check before any new enrollment. The PI remains responsible for oversight; travel does not transfer that responsibility to the coordinator.